Developer · United States

Emalex Biosciences Inc.

Emalex Biosciences was a Chicago-based clinical-stage biopharmaceutical company (a Paragon Biosciences portfolio company) developing ecopipam, a first-in-class selective dopamine D1 receptor antagonist, for pediatric Tourette syndrome and other CNS disorders. The company was acquired by Teva Pharmaceutical Industries in June 2026.

emalexbiosciences.com ↗

1compound
1program
1indication
Filed (NDA)lead asset

Phase distribution

  • Filed (NDA)1

Modality

  • Small molecule 1

Mechanism focus

Pipeline (1)

Deals & partnerships

  • EcopipamLed by Teva Pharmaceutical Industries Ltd.Licensor Psyadon Pharmaceuticals, Inc.
  • Jun 10, 2026AcquisitionTeva acquires Emalex BiosciencesTeva Pharmaceutical Industries completed its acquisition of Emalex Biosciences, adding the NDA-ready ecopipam (a first-in-class selective dopamine D1 receptor antagonist for pediatric Tourette syndrome) to its neuroscience pipeline. Terms: $700M upfront cash, up to an additional $200M in commercial milestone payments, plus net sales-based royalties (subject to regulatory approval). Announced April 29, 2026; closed June 10, 2026.Ecopipamsource ↗
  • Aug 14, 2018AcquisitionEmalex Biosciences acquires Psyadon Pharmaceuticals, gaining ecopipam rightsEmalex Biosciences acquired Psyadon Pharmaceuticals and the exclusive rights to develop, register and market ecopipam, a new chemical entity with orphan drug designation, for the treatment of pediatric Tourette syndrome in patients under 16 years of age. Psyadon had advanced ecopipam through Phase 2b prior to the acquisition.Ecopipamsource ↗

Catalysts · 0 upcoming · 2 reported

Recently reported

  • 2026-06-18

    EcopipamforTourette syndromeRegulatory

    Teva submitted the U.S. NDA for ecopipam in pediatric Tourette syndrome (guided for 2H 2026; submitted 2026-06-18).

    source ↗

  • 2026-05-26met

    EcopipamforTourette syndromeTopline data

    D1AMOND Phase 3 met primary and secondary endpoints: ecopipam delayed time to relapse vs placebo in pediatric (HR=0.5, p=0.0084) and combined (HR=0.5, p=0.0050) Tourette populations; published in JAMA Neurology.

    source ↗

Recent activity

  • Jun 18, 2026ReadoutEcopipam·Tourette syndromeTeva submitted the U.S. NDA for ecopipam in pediatric Tourette syndrome (guided for 2H 2026; submitted 2026-06-18).source ↗
  • May 26, 2026ReadoutEcopipam·Tourette syndromemetD1AMOND Phase 3 met primary and secondary endpoints: ecopipam delayed time to relapse vs placebo in pediatric (HR=0.5, p=0.0084) and combined (HR=0.5, p=0.0050) Tourette populations; published in JAMA Neurology.source ↗
  • Feb 4, 2025Phase changeEcopipam·Tourette syndromePhase 3D1AMOND Phase 3 completed (primary completion 2025-01-13; study completion 2025-02-04); met primary and secondary endpoints.source ↗
  • Jan 31, 2023Phase changeEcopipam·Tourette syndromePhase 3Pivotal Phase 3 randomized-withdrawal study D1AMOND (NCT05615220) started (first patient dosed).source ↗
  • Sep 23, 2021Phase changeEcopipam·Tourette syndromePhase 2Phase 2b in children/adolescents with Tourette syndrome (NCT04007991, n=153) completed (primary completion 2021-09-23).source ↗

Competitive landscape

Other companies developing against Emalex Biosciences Inc.'s targets or indications.

Leadership & advisors (25)